[How far has non-invasive testing become a surrogate endpoint for the research and development of new drugs for metabolic dysfunction-associated steatohepatitis?]
{{output}}
The research and development of new drugs for metabolic dysfunction-associated steatohepatitis still leads to a high screening failure rate and low efficiency with the repeated liver biopsy as the primary endpoint. Currently, non-invasive testing has been wide... ...
